Miracle of miracles, a benefactor stepped in at the last minute, and the FM is back from the brink. As a result, I’m also back to write another day

The FM was there at the gestation of my career in finance, providing advice and inspiration, and it has been a privilege to contribute to it

Novo Nordisk’s growth trajectory is slowing. Could it be that people are rejecting Wegovy and Ozempic in favour of simpler weight-loss methods?

Are the markets getting it wrong on South Africa’s ‘growing risk profile’, as one WSJ commentator has suggested? Or are they, rightly, seeing the bigger picture?

Proteas, fynbos and Babylonstoren’s hospitality impress at the Chelsea Flower Show — and the price was just right

On turning 18, winning under pressure and universal values that unite us

Sometimes you just have to sit tight and ignore the noise — what goes down must go up again

Sorry, dear readers, but if Donald Trump was a more realistic president, I wouldn't be forced to write about him

From Covid crashes to Trump’s tariffs — why investors must stay the course

The emergence of DeepSeek did not influence the Magnificent 7 as badly as some feared; three of these shares ended higher soon after the announcement of its development